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Myotonic dystrophy (MD), the most common inherited myopathy, is associated with high 
cardiovascular mortality1. A preliminary analysis of the DM1 Heart Registry (URL: 
ClinicalTrials.gov. Unique identifier: NCT01136330), a comprehensive database that captures 
information relative to the cardiac management of adults presenting to our center with MD2, 
revealed a high prevalence of venous thromboembolism (VTE). We designed this study to 
estimate the risk of VTE in MD and its survival consequences. 
We retrospectively analyzed the data relative to patients referred to our center between 
January 2000 and January 2015, including 1148 with MD and 1662 with other inherited 
myopathies (facioscapulohumeral, dystrophinopathy, mitochondrial, glycogen- and lipid-
storage diseases, limb-girdle muscular dystrophies, nucleopathies, collagen VI–related 
disorders, myofibrillar, and congenital). This study was approved by our local Ethics 
Committee, and all patients granted their written informed consent to participate. We 
compared patient baseline characteristics using Wilcoxon rank-sum or Fisher exact tests as 
appropriate. VTE, defined as ≥1 episode of deep vein thrombosis or pulmonary embolism, was 
analyzed in a competing-risks framework, with death as a competing event. Cumulative 
incidences (probability of occurrence over follow-up), hazard ratios (HRs), and cumulative 
hazards of VTE were estimated. We searched for predictors of the hazard of VTE using Cox 
proportional hazards models for the cause-specific hazards on the time of study scale, with 
follow-up beginning on the date of inclusion in the study until the occurrence of VTE, death, 
or last follow-up, whichever occurred first. All patient characteristics described in the results 
were included in this analysis, including all variables from our database that represent known 
VTE risk factors. 
At first presentation, patients with MD, compared with others, were older (40 [29–51] years 
versus 39 [25–52] years; P=0.029); had a lower proportion of men (556 [48.4%] versus 990 
[59.6%]; P<0.0001); had a more frequent personal history of VTE (40 [3.5%] versus 9 
[0.5%]; P<0.0001), heart failure (12 [1.0%] versus 128 [7.7%]; P<0.0001), and conduction 
disease (461 [40.2%] versus 195 [11.7%]; P<0.0001); were treated with vitamin K antagonists 
(32 [3.0%] versus 25 [1.5%], P=0.009) and estrogen contraceptives (137 [11.9%] versus 140 
[8.4%], P=0.002); and had a lower Walton score3 (1 [0–3] versus 3 [1–6]; P<0.0001) and less 
frequent ambulation loss (80 [6.9%] versus 405 [24.4%], P<0.0001). A similar prevalence was 
observed for obesity (123 [10.9%] versus 183 [11.2%]; P=0.85), respiratory failure (133 
[13.2%] versus 257 [15.8%]; P=0.071), and cancer (31 [2.8%] versus 33 [1.9%]; P=0.25). VTE 
occurred in 82 patients with MD over a 10.9-year follow-up (95% CI, 2.4–14.7), representing 
an 8.3 per 1000 patient-year incidence (95% CI, 6.6–10.3) and a 10.3% cumulative incidence 
(95% CI, 7.8–12.7), and in 20 patients with other myopathies over a median 8.5-year follow-
up, representing a 1.6 per 1000 patient-year incidence (95% CI, 1.0–2.5) and a 2.2% 
cumulative incidence (95% CI, 1.1–3.3; Figure A). VTE developed in the absence of 
predisposing factors in 48 patients with MD (58.5%) and in 6 with other myopathies (30.0%). 
Among the 1148 patients with MD, 253 (22.0%) died during follow-up, 39 suddenly. Among 
the 83 cardiovascular deaths, pulmonary embolism was the cause of death in 26 patients 
(10.3% of all deaths) and the second most frequent cause of cardiovascular death (31.3%) 
after sudden cardiac death (Figure B). 
In multivariable analysis, among the 2810 patients with inherited myopathies, predictors of 
VTE were MD (HR, 5.35; 95% CI, 2.85–10.0; P<0.0001), increasing age (HR, 1.02; 95% CI, 1.00–
1.03; P=0.031), personal history of VTE (HR, 4.56; 95% CI, 2.28–9.10; P=0.0001), obesity (HR, 
2.66; 95% CI,1.64–4.32; P<0.0001), high Walton score (HR, 1.20; 95% CI, 1.09–1.32; P=0.0003), 
cancer (HR, 4.32; 95% CI, 2.05–9.08; P<0.0001), conduction disease (HR, 1.63; 95% CI, 1.06–
2.51; P=0.025), and ambulation loss in patients with MD (HR, 7.18; 95% CI, 1.88–
27.4; P=0.004). The standardized rate ratio for VTE between our sample and an age- and sex-
matched community-based French population4 was higher in MD (7.53; 95% CI, 6.02–9.28) 
than in other myopathies (1.23; 95% CI, 0.77–1.85; P<0.0001). 
The association between MD and VTE has not been previously reported and is supported in 
this study by the magnitude of the risk of VTE observed in patients with MD, its independence 
from the muscular functional status, and a majority of idiopathic events. The burden 
represented by VTE on survival was remarkably heavy, with pulmonary embolism 
representing one of the most common causes of death. Although the optimal VTE risk 
mitigation strategy for these patients remains to be defined, our study supports a more 
systematic VTE prophylaxis that should be extended to any medical or surgical setting. The 
association between MD and VTE may rely on the complex pathogenic mechanisms of MD, 
which involve the toxic effect of RNA, resulting in alterations of several cellular functions such 
as alternative splicing5. One might hypothesize that missplicing of factors involved in the 
coagulation process contributes to the development of VTE. 
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Figure. A, Cumulative hazard of venous thromboembolism (VTE) during follow-up according 
to the disease on the time of study scale (The Nelson-Aalen estimator was used to generate 
the curves. Error bars indicate pointwise 95% CIs) and B, distribution of the causes of 253 
deaths in patients with myotonic dystrophy. MD indicates myotonic dystrophy. 
 
